Vistagen (NASDAG:VTGN) announced positive results from its exploratory Phase 2a study of PH284, an investigational pherine nasal spray for cancer cachexia— a condition characterized by appetite loss and severe wasting associated with chronic illnesses.
According to Vistagen, PH284 demonstrated a higher mean subjective feeling of hunger compared to a placebo and appeared safe and well-tolerated, with an adverse event profile comparable to that of a placebo in a population with advanced cancer.
“We are highly encouraged by the potential of PH284 to improve the quality of life for those challenged by the debilitating impacts of cancer cachexia,” stated Shawn Singh, president and CEO of Vistagen.
“Loss of appetite from cancer and other illnesses not only negatively impacts overall health and quality of life, but can also reduce the effectiveness of critical therapies, such as chemotherapy in cancer patients. PH284 is our fifth novel investigational pherine, each supported by positive Phase 2 or later clinical data and placebo-like tolerability, underscoring the breadth, diversity and potential of our neuroscience pipeline to address multiple significant unmet needs,” Mr. Singh added.
